FAQ on Soligenix Inc.'s CiVax Development and the Ongoing COVID-19 Threat

What is CiVax and who is developing it?

CiVax is a proprietary, heat-stable COVID-19 subunit vaccine candidate being developed by Soligenix Inc. to address the ongoing threat of COVID-19.

Why is the development of CiVax significant?

The development of CiVax is significant because it offers a potential solution to the persistent danger of COVID-19, with preclinical studies showing it can induce rapid and broad protection against multiple variants of the virus.

How does CiVax work?

CiVax works as a subunit vaccine, focusing on specific parts of the virus to induce an immune response, and its heat-stable nature makes it easier to store and distribute.

What recent data highlights the ongoing threat of COVID-19?

Recent WHO data indicates a 16% decrease in new COVID-19 cases but a 28% increase in deaths during a 28-day period from Jan. 6 to Feb. 2, 2025, underscoring the virus’s persistent danger.

Where can I find more information about Soligenix Inc. and CiVax?

More information about Soligenix Inc. and its CiVax vaccine candidate is available in the company’s newsroom at https://ibn.fm/SNGX.

What are the implications of CiVax’s heat-stable nature?

The heat-stable nature of CiVax implies easier storage and distribution, potentially making it more accessible in regions with limited refrigeration capabilities.

How does the current situation of COVID-19 in the United States look?

As of April 11, 2025, the CDC reported low levels of acute respiratory illnesses, including COVID-19, in the United States, but the virus continues to circulate with the potential for new variants.

What should people know about the ongoing COVID-19 threat?

People should be aware that despite a decrease in cases, COVID-19 remains a significant global health threat, with an increase in deaths, highlighting the need for effective vaccines like CiVax.